Navigation Links
Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients

American Journal of Surgery Study Reveals Conclusive Findings

NEWPORT NEWS, Va., Feb. 27 /PRNewswire/ -- Women facing a recent breast cancer diagnosis may find additional cancer in the same or opposite breast with further testing using Breast-Specific Gamma Imaging (BSGI) according to a study published in the February 2009 "American Journal of Surgery." BSGI detected additional or more extensive breast cancer in the same or opposite breast in 10.9 percent of newly diagnosed patients according to the study.

BSGI, a molecular breast imaging technique, is a follow-up to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, compact field-of-view gamma camera, optimized to perform BSGI.

"The research is important because it helps clarify the role of BSGI in newly diagnosed breast cancer patients. We have found that these women can have more extensive disease that is not detected by mammography or ultrasonography. This is especially helpful in patients with dense breast tissue where additional evaluation of the remaining breast tissue is necessary," said Nathalie Johnson, M.D., general surgeon and surgical oncologist at Good Samaritan Hospital, Portland, Ore.

Johnson and her team conducted a retrospective review from two Portland, Ore. community-based breast imaging centers of newly diagnosed breast cancer patients in whom BSGI was performed as part of the imaging work-up. BSGI detected additional or more extensive malignancy in the same or opposite breast in 10.9 percent of newly diagnosed breast cancer patients. Only 7.2 percent incurred an additional work-up. The study concluded that BSGI provides accurate evaluation of remaining breast tissue in newly diagnosed breast cancer patients with few false-positive readings.

BSGI has comparable sensitivity, but superior specificity when compared to magnetic resonance imaging (MRI), which leads to improved management of the newly diagnosed breast cancer patient. Sensitivity refers to the ability of an imaging technique to detect the presence of disease. Specificity refers to the technique's ability to detect that disease is actually not present.

"The biggest benefit of BSGI is the specificity. The sensitivity of BSGI is on par with MRI, but the specificity is higher than MRI. In addition, when compared to MRI, BSGI is less expensive and easier to use for patient and physician," said Johnson.

Study Results

A total of 138 patients (69 invasive ductal carcinoma, 20 invasive lobular carcinoma, 32 ductal carcinoma in situ, and 17 mixtures of invasive ductal carcinoma, invasive lobular carcinoma, or ductal carcinoma in situ and other) were reviewed. Twenty-five patients (18.1%) had a positive BSGI study for cancer at a site other than their known cancer, or more extensive disease than was detected from previous imaging. Fifteen patients (10.9%) were positive for a synchronous or more extensive cancer in the same or opposite breast. Five patients had benign findings on pathology, five benign on ultrasound follow-up (false-positive rate, 7.2%). Findings converted seven patients to mastectomy, one patient to neoadjuvant chemotherapy, and seven patients were found to have previously undetected contralateral cancer. The positive predictive value for BSGI was 92.9%.

The full study can be found in The American Journal of Surgery, Vol 197, No 2, February 2009.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit

SOURCE Dilon Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
2. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
3. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
4. Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management
5. Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
6. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
7. ETEX Corporation Announces CE Mark of Beta-bsm and Gamma-bsm
8. What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
9. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
10. Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
11. STERIS Isomedix Services Offers Gamma Engineering Run Program
Post Your Comments:
(Date:11/24/2015)... N.J. (PRWEB) , ... November 25, 2015 , ... ... delivery technologies and development solutions for drugs, biologics, consumer health and global clinical ... will present at the upcoming Clinical Trial Supply East Asia Conference, to be ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... Marne, MI (PRWEB) , ... November 24, 2015 , ... ... has released a series of recent video interviews with some of the staff members ... life at the residential treatment facility, as well as some of the things that ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- Avery Biomedical Devices (ABD), manufacturer of the Avery ... of Anders Jonzon , MD; Ph.D. as clinical ... Dr. Jonzon is a Physiologist and consultant in ... Uppsala and Children,s Hospital, Karolinska, Stockholm, Sweden ... the Cardiovascular Institute (UCSF). His research has covered circulation, ...
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
(Date:11/24/2015)... 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... Services, Education and Human Resources will be presenting in the ... Health Plan Strategies for a Dynamic Market" on Dec. 1, ... a consultant with the Cambridge Advisory Group, where she leads ... The webinar will discuss the rapid growth of oral ...
Breaking Medicine Technology: